Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Brain Sciences

Edmond and Lily Safra Chair. Head of Department



+44 (0)20 7594 2855p.matthews




Ms Siobhan Dillon +44 (0)20 7594 2855




E502Burlington DanesHammersmith Campus






BibTex format

author = {LaRocca, NG and Hudson, LD and Rudick, R and Amtmann, D and Balcer, L and Benedict, R and Bermel, R and Chang, I and Chiaravalloti, ND and Chin, P and Cohen, JA and Cutter, GR and Davis, MD and DeLuca, J and Feys, P and Francis, G and Goldman, MD and Hartley, E and Kapoor, R and Lublin, F and Lundstrom, G and Matthews, PM and Mayo, N and Meibach, R and Miller, DM and Motl, RW and Mowry, EM and Naismith, R and Neville, J and Panagoulias, J and Panzara, M and Phillips, G and Robbins, A and Sidovar, MF and Smith, KE and Sperling, B and Uitdehaag, BM and Weaver, J and Multiple, Sclerosis Outcome Assessments Consortium MSOAC},
doi = {10.1177/1352458517723718},
journal = {Multiple Sclerosis Journal},
pages = {1469--1484},
title = {The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability},
url = {},
volume = {24},
year = {2018}

RIS format (EndNote, RefMan)

AB - BACKGROUND: The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed by the National MS Society to develop improved measures of multiple sclerosis (MS)-related disability. OBJECTIVES: (1) To assess the current literature and available data on functional performance outcome measures (PerfOs) and (2) to determine suitability of using PerfOs to quantify MS disability in MS clinical trials. METHODS: (1) Identify disability dimensions common in MS; (2) conduct a comprehensive literature review of measures for those dimensions; (3) develop an MS Clinical Data Interchange Standards Consortium (CDISC) data standard; (4) create a database of standardized, pooled clinical trial data; (5) analyze the pooled data to assess psychometric properties of candidate measures; and (6) work with regulatory agencies to use the measures as primary or secondary outcomes in MS clinical trials. CONCLUSION: Considerable data exist supporting measures of the functional domains ambulation, manual dexterity, vision, and cognition. A CDISC standard for MS ( ) was published, allowing pooling of clinical trial data. MSOAC member organizations contributed clinical data from 16 trials, including 14,370 subjects. Data from placebo-arm subjects are available to qualified researchers. This integrated, standardized dataset is being analyzed to support qualification of disability endpoints by regulatory agencies.
AU - LaRocca,NG
AU - Hudson,LD
AU - Rudick,R
AU - Amtmann,D
AU - Balcer,L
AU - Benedict,R
AU - Bermel,R
AU - Chang,I
AU - Chiaravalloti,ND
AU - Chin,P
AU - Cohen,JA
AU - Cutter,GR
AU - Davis,MD
AU - DeLuca,J
AU - Feys,P
AU - Francis,G
AU - Goldman,MD
AU - Hartley,E
AU - Kapoor,R
AU - Lublin,F
AU - Lundstrom,G
AU - Matthews,PM
AU - Mayo,N
AU - Meibach,R
AU - Miller,DM
AU - Motl,RW
AU - Mowry,EM
AU - Naismith,R
AU - Neville,J
AU - Panagoulias,J
AU - Panzara,M
AU - Phillips,G
AU - Robbins,A
AU - Sidovar,MF
AU - Smith,KE
AU - Sperling,B
AU - Uitdehaag,BM
AU - Weaver,J
AU - Multiple,Sclerosis Outcome Assessments Consortium MSOAC
DO - 10.1177/1352458517723718
EP - 1484
PY - 2018///
SN - 1352-4585
SP - 1469
TI - The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
T2 - Multiple Sclerosis Journal
UR -
UR -
UR -
VL - 24
ER -